Unmet needs in chronic cough are significant, affecting millions globally:

• ~7M RCC/UCC patients in the US (~200M globally)
• No approved antitussive drugs for RCC/UCC
• Guideline‑recommended behavioral therapy for RCC/UCC is proven - just largely unavailable (<250 providers in the US)

Behavioral Cough Suppression Therapy (BCST) is Proven To Work

• >15 studies (4 RCTs, 11+ prospective cohorts/series, 4 languages) with ~500 unique patients evaluated
• Mean LCQ improvement: +4 - 7.5 points (3-4x MCID)
• Mean 24-h cough-count reduction: 30-50% (41% in largest RCT)
• No adverse events - excellent safety

Digital Therapeutic Opportunity - why now?

• Proven mechanism – neuroplastic retraining of cough reflex
• Compelling effect size – equal or superior to top antitussive molecules in development, potential for “software + pill”
• No safety liabilities
• Telehealth validation – 88% responder rate in video-BCST cohort
• Pathways to reimbursement are increasing worldwide

WHAT IT IS?

• Digitally delivered behavioral cough suppression therapy (BCST)
• Designed for high engagement to promote strong adherence
• Continuous, passive cough monitoring
• Biofeedback loop enabling tailored personalization

HOW IT WORKS?

• AI passively monitors cough frequency and patterns
• App delivers proven techniques to suppress cough
• Real-time efficacy tracking and biofeedback enables personalization and ensures adherence

CLINICALLY & COMMERCIALLY VALIDATED

• BCST has demonstrated up to 88% effectiveness in reducing cough frequency
• Safe, easy, and with zero side effects
• In development as a prescription-only regulated SaMD for the Japanese market‍

Latest in Publications

View All

PublicationsAbstracts

A Prospective Decentralized Pilot Study Assessing a Digital Therapeutic Feature Inside CoughPro: For Adults with RCC/UCC

Hyfe pilot study tests a digital therapeutic combining passive cough monitoring with behavioral suppression techniques delivered through the CoughPro app.

04.12.2025

PublicationsPeer-reviewed

The value of continuous cough monitoring: a narrative review

This narrative review by Hyfe's R&D team makes the case that continuous cough monitoring (CCM), powered by acoustic AI, transforms cough from a subjective symptom into a quantifiable digital biomarker.

30.11.2025

PublicationsAbstracts

Azithromycin and Oesophageal Motility in Chronic Respiratory Disease: A Feasibility Trial

Independent ERS 2025 NeuroCOUGH trial uses the Hyfe Cough Tracker to test feasibility of studying azithromycin's effect on cough and oesophageal motility.

18.11.2025

PublicationsAbstracts

Azithromycin and continuous cough monitoring: an open-label trial

Independent ERS 2025 trial uses the Hyfe Cough Tracker to show azithromycin reduces objective cough frequency by week one in chronic respiratory disease.

18.11.2025

Dive into the science. Explore our publications.

READ MORE